BeVigilant - RAPID Platform

The Vigilant Biosciences^® BeVigilant^™ RAPID Test is based on patented technology that assesses multiple biomarkers to aid clinicians in the early detection of oral cancer. The simple procedure is easy to administer and non–invasive for the patient.

With the BeVigilant^™ RAPID Platform, clinicians can get a simple and accurate^† assessment to aid in the early detection of oral cancer potentially before lesions are visible. The BeVigilant RAPID Platform provides a qualitative result at the point–of–care, reporting a low, moderate or elevated levels of oral cancer biomarkers.

BeVigilant^™ RAPID Test is an easy–to–use, accurate,^† qualitative tool for frontline healthcare clinicians assessing potentially at–risk patients for oral cancer.

Provide test results during the patient visit with the BeVigilant^™ RAPID Reader. This advanced immunochromatography reader captures the test data and uploads to the BeVigilant^™ Portal for quick and effortless patient reporting.

View and monitor patients’ known risk–factors and test data in easy–to–read graphs and reports in the BeVigilant^™ Portal.

The BeVigilant^™ RAPID Test is CE Marked and available in select markets outside the United States.

The BeVigilant^™ RAPID Test Complements Regular Check-Ups for a More Comprehensive Oral Exam.

The BeVigilant^™ RAPID Platform includes the BeVigilant^™ RAPID Test, RAPID Reader and BeVigilant^™ Portal to provide a qualitative test result at the point-of-care, reporting a low, moderate or elevated risk levels of oral cancer biomarkers.

The BeVigilant^™ RAPID Test + RAPID Reader is a value-added offering allowing clinicians to integrate easily into their practice as part of the patients’ regular care